Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Stock Information for AtlasClear Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AtlasClear Holdings Inc.

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.